Budget 2026: India to Become Biopharma Powerhouse with ₹10,000 Crore 'Biopharma Shakti' Scheme

• Finance Minister Nirmala Sitharaman unveiled the 'Biopharma Shakti' scheme with a ₹10,000 crore proposal over five years.
• The initiative aims to establish India as a global biopharma manufacturing hub, focusing on biologics for modern treatment.
• Special emphasis will be placed on biopharma-centric networks to boost research, production, and innovation.
• The scheme seeks to make medicines for serious diseases more affordable and enhance India's global pharma market presence.
• Following the announcement, shares of Biocon, Piramal Pharma, Sun Pharma, and Torrent Pharma saw an increase, indicating market approval.

Why It Matters: Budget 2026 introduces 'Biopharma Shakti' to transform India into a global biopharma manufacturing hub.